At low doses (150-300 mg standardized extract or 1-2 g dried leaf as tea):

• Mild "softening" of edge — subjective baseline anxiety drops a fraction.
• Slight warmth/relaxation in the chest, minor reduction in heart-rate awareness (the palpitation-reduction phenomenology from Alijaniha 2015).
• No cognitive impairment; some users report mild cognitive enhancement at this tier — consistent with Kennedy 2002 nontrivial-load cognitive benefit.
• Onset 30-60 min oral; lemon balm tea slightly faster due to fluid + thermal vehicle.
• Duration 2-4 hours.

At moderate doses (300-600 mg standardized; the "Cases 2011 / Kennedy 2004" RCT-sweet-spot):

• Clear subjective anxiolysis — described as "background noise of mind quiets" or "the sub-bass of worry turns down." Not euphoric. Not sedating in the daytime.
• Sleep onset improved if taken 30-60 min pre-bed.
• Reduced HR variability around stressors; subjective stress-response attenuation (Kennedy 2004 DISS effect).
• No significant cognitive impairment at this tier; arguably slight gain on sustained-attention tasks.
• Duration 4-6 hours.

At high doses (>900 mg standardized extract or >3 g leaf):

• Frank drowsiness in some users; cognitive impairment becomes detectable (Kennedy 2002 high-dose memory benefit + attention cost; Kennedy 2006 +valerian high-dose paradoxical anxiogenesis).
• Dose-ceiling reached — more is not better. Practical lesson: stay in the standardized 300-600 mg window unless specifically titrating for acute sleep induction.

Onset/peak/duration generalization for Dylan's archetype:

• 300-400 mg standardized (~3-5% rosmarinic acid) at 30-45 min before target effect.
• Peak subjective effect 60-90 min.
• Useful window 3-5 hours.
• No "comedown" — fades rather than crashes.
• Repeatable nightly without observable tolerance over 4-week windows (Cases 2011 + open-label experience).

• No documented pharmacological tolerance in clinical trials up to 4-month chronic use (Akhondzadeh 2003). Effect appears stable.
• Subjective tolerance to the novelty — some users report the "first dose felt magical, now it just feels like baseline" pattern (common across all mild anxiolytics; usually reflects regression toward mean expectancy rather than receptor adaptation).
• No need to cycle for receptor recovery. The GABA-T inhibition is mild, reversible, and operates well below the dynamic range where receptor down-regulation matters.
• Recommended schedule for Dylan: Use PRN for pre-sleep or pre-stressor windows; daily-use is OK during high-load business/training blocks (2-4 weeks). No structured washout needed.

Synergistic with

• L-theanine (200 mg) — community's #1 co-mention (246 dc reports). Mechanistic complement (theanine = mild α2/glutamate modulation + α-wave EEG; lemon balm = GABA-T inhibition). Subjectively smoother than either alone; common evening protocol.
• Chamomile (200-400 mg apigenin-standardized) — apigenin is a partial benzodiazepine-site GABA-A modulator; complementary mild anxiolysis. Classic "bedtime tea" stack works pharmacologically too.
• Passionflower (250-500 mg) — chrysin + other flavonoid GABA-A PAMs; complementary mechanism; mild additive sedation.
• Magnolia bark (honokiol/magnolol) — GABA-A PAM + cortisol reduction; reasonable evening stack for the "high-cortisol night-owl" use case Dylan may encounter on heavy-business or post-spar nights.
• Valerian at low-to-moderate doses (≤300-500 mg of root extract; Cerny 1999 / German E Commission–consistent dosing) — synergistic sleep onset. Cap combined dose — Kennedy 2006 showed 1800 mg of combined extract was paradoxically anxiogenic. Stay at low-to-moderate combined doses.
• GABA (oral) — community co-mention #4 (93 reports); GABA oral BA is poor, so the rationale is weak, but the subjective stack is popular and at typical doses is benign.
• Glycine (3 g pre-sleep) — mild sleep-onset hypothermia + parasympathetic shift; complementary to lemon balm's central GABAergic effect.

Avoid stacking with

• Benzodiazepines, Z-drugs, phenibut, GHB/GBL, baclofen, gabapentinoids — additive GABAergic CNS depression. The downside risk in Dylan's archetype is low (no current Rx anxiolytic use) but worth knowing if anyone in his future overlap-prescribing window comes up.
• Alcohol — additive sedation; Dylan's profile is zero-alcohol baseline, so not directly relevant.
• High-dose ashwagandha + lemon balm + L-theanine simultaneously — usually fine but can produce excessive next-morning sedation; if stacking three anxiolytics, reduce each individually.
• SSRIs / SNRIs / MAOIs — community dc data flags 11 serotonin-syndrome mentions. The mechanistic basis is thin (lemon balm is not a primary serotonergic agent), but defaulting to caution at high doses or with concurrent MAOI is reasonable. Not relevant for Dylan currently.
• Thyroid hormone replacement (levothyroxine) — theoretical signal from animal studies of mild TSH/T4 suppression. Take lemon balm 4+ hours apart from levothyroxine to minimize any potential interaction. Not relevant for Dylan currently.

Neutral / safe co-administration

• All of Dylan's locked V4 stack supplements — magnesium, NAC, citicoline, PS, DHA, curcumin, rhodiola, glycine, D3/K2, beta-alanine, vitamin C — no known interactions.
• Modafinil — no significant interaction; lemon balm in the evening can blunt residual modafinil-driven sympathetic tone and is a reasonable pre-sleep pair on dose days.
• Creatine, taurine, melatonin — neutral; melatonin + lemon balm is a common evening-stack pairing (104 dc co-mentions).
• Most peptides (BPC-157, TB-500, Selank, Semax, Adamax) — neutral.

• CYP3A4 mild inhibition (in vitro evidence) — theoretical caveat for CYP3A4 substrates (statins, certain immunosuppressants, calcium channel blockers, some benzodiazepines, midazolam, sildenafil). Clinical significance at typical doses (≤600 mg standardized) is likely small but not zero. Practical takeaway for Dylan: no current Rx CYP3A4 substrates; not a current concern. If he ever starts a CYP3A4-narrow-therapeutic-window drug (rare in his archetype), revisit.
• GABAergic CNS depressants — additive sedation (see Stacking).
• Thyroid medication — theoretical mild TSH/T4 interference (see Side effects).
• Hormonal contraceptives — no clinically documented interaction.
• Anticoagulants (warfarin, DOACs) — no clinically documented interaction; rosmarinic acid has minor antiplatelet activity in vitro but human-clinical signal is absent.
• Pre-anesthesia / pre-surgery — discontinue 2 weeks before elective surgery as a standard cautious practice with any sedative herb (theoretical anesthesia potentiation). No documented adverse outcome.

• No actionable PGx for lemon balm response as of 2026. Rosmarinic acid metabolism is non-CYP-dominant (esterase hydrolysis + UGT glucuronidation); minor inter-individual variability not currently genotype-stratified.
• CYP3A4 / CYP3A5 polymorphism — relevant only if combining lemon balm with CYP3A4-substrate drugs in tight-therapeutic-window scenarios. Not applicable to Dylan.
• GABA-A / GABA-B receptor variants — implicated in benzodiazepine response and alcohol use disorder; presumed to modulate lemon balm sensitivity but not directly studied.
• COMT, BDNF variants — could plausibly affect subjective stress-buffering response (the Yoo 2011 BDNF/neurogenesis pathway). Speculative; no validated genotype-stratified dosing.
• Practical takeaway: Once Dylan's 23andMe results land (~June 2026), no specific lemon balm dose adjustment will be indicated. The herb is benign across genotypes.

Sourcing-difficulty rating: easy. OTC, unscheduled, widely available, no Rx required.

For Dylan specifically: Start with a standardized 3-7% rosmarinic acid extract from a mid-tier brand (Now Foods, Jarrow, NutraBio — all ~$0.30/dose). If he runs through a 60-cap bottle and feels marginal effect, upgrade to phytosome (Thorne or Indena-sourced) before declaring it a non-responder. Tea is an enjoyable parallel "ritual dose" but not the primary delivery vehicle for testing efficacy.

Baseline (before starting, optional)

• Subjective anxiety VAS (1-10) baseline for 7 days pre-use — give yourself something to compare to.
• Sleep onset latency (subjective: how long it takes to fall asleep) baseline for 7 days.
• Resting HR + HRV (Oura ring, Apple Watch, or 7-day Polar chest-strap average) — Alijaniha 2015 evidence is on heart palpitations; HRV/RHR is the closest proxy biomarker.
• TSH + fT4 at annual physical if planning chronic daily use — establish baseline for the theoretical hypothyroid signal.

During use

• Subjective anxiety VAS + sleep onset latency — weekly check, 4-8 week window. The primary efficacy biomarker.
• Morning HRV / RHR — Oura/ring data should trend toward better baseline if lemon balm is shifting evening sympathetic tone. Subtle effect, treat as supporting rather than primary.
• Sleep architecture (Oura) — REM and deep sleep should not be suppressed (unlike with alcohol or high-dose THC); some users report mild deep-sleep enhancement at evening doses.

Post-discontinuation

• No rebound expected. Subjective anxiety should return to baseline within 1-3 days of stopping. If it doesn't, the issue was likely the underlying stressor, not the herb.
• TSH check at annual physical for chronic users; reassurance check.